CORRECTION article

Front. Pharmacol., 24 April 2025

Sec. Respiratory Pharmacology

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1591443

Corrigendum: Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting

  • 1. Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, China

  • 2. College of Clinical Medicine, Jilin University, Changchun, China

  • 3. Department of Molecular Biology, Max Planck Institute for Infection Biology, Berlin, Germany

  • 4. Laboratory of Infection Oncology, Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel and University Hospital Schleswig-Holstein, Kiel, Germany

  • 5. Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

  • 6. Department of General Surgery, Capital Institute of Pediatrics’ Children’s Hospital, Beijing, China

Article metrics

View details

1,4k

Views

324

Downloads

In the published article, there was an error in the Funding statement. The funding statement in the article is written incorrectly as “Jilin Provincial Science and Technology Development Plan Project, 20220204115YY.” The correct statement is “Jilin Province science and technology development plan project:YDZJ202301ZYTS007”. The correct Funding statement appears below.

Statements

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. The study was supported by Jilin Province science and technology development plan project:YDZJ202301ZYTS007; Jilin Province Medical and Health Personnel Special Fund (JLSWSRCZX2023). The funding source provided financial support for the project but had no role in the study design, data collection, analysis, interpretation, or writing of the manuscript.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

PI3K/Akt/mTOR pathway, lung cancer, PI3K inhibitors, Akt inhibitors, mTOR inhibitors, natural products, combined therapy

Citation

Qiang M, Chen Z, Liu H, Dong J, Gong K, Zhang X, Huo P, Zhu J, Shao Y, Ma J, Zhang B, Liu W and Tang M (2025) Corrigendum: Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting. Front. Pharmacol. 16:1591443. doi: 10.3389/fphar.2025.1591443

Received

11 March 2025

Accepted

31 March 2025

Published

24 April 2025

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

16 - 2025

Updates

Copyright

*Correspondence: Wei Liu, ; Mingbo Tang,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics